BioSpace News Archive

Biofrontera Inc. (“Biofrontera” or the “Company”) (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Wednesday, November 30, 2022, at 12:00 PM EST, Monday, December 5, 2022, at 1:00 PM CST, Friday, December 9, 2022 at 12:00 PM EST and Monday, December 19, 2022 at 1:00 PM PST.

Hospitals and Imaging Centers face increasing demands on their operational and capital budgets along with higher patient expectations and regulatory requirements.

UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, today announced new findings from a landmark pivotal study.

CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers.

MicrobioSeq is on behalf of the microbial genomics division of CD Genomics, headquartered in New York, USA.

A U.S. study of BoneView by GLEAMER AI software led by Ali Guermazi, MD, PhD, Chief of Radiology at VA Boston Healthcare System and Professor of Radiology and Medicine at Boston University School of Medicine, has been honored with the 2022 Alexander R.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022.

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced that Lyn Baranowski and Marc Schneebaum, Avalyn Pharma’s chief executive and chief financial officers will participate in the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022.

The global influenza vaccine market was estimated at USD 7.02 billion in 2021 and it is expected to surpass around USD 15.13 billion by 2030, poised to grow at a CAGR of 8.91% from 2022 to 2030.

The global microbiome sequencing outsourcing services market is expected to register significant growth over the forecast period. Microbiomes are microorganisms living in the human body.